Novaliq has started the randomization of patients in ESSENCE-2, a phase 3 clinical trial of CyclASol, a topical anti-inflammatory and immunomodulating ophthalmic solution for the treatment of dry eye disease, according to a press release.
CyclASol (cyclosporine A 0.1% in EyeSol) is a water-free formulation with early-onset efficacy and improved tolerability in patients with dry eye disease, the release said. ESSENCE-1, a previous phase 2/3 clinical trial, showed statistically significant improvements in sign and symptom endpoints at 4 weeks.
“If ESSENCE-2 is successful, we will have
Uncategorized